A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase

Trial Profile

A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Bosutinib (Primary) ; Inotuzumab ozogamicin (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Sep 2016 Planned number of patients changed from 40 to 80.
    • 19 Apr 2015 New source identified and integrated as M.D. Anderson Cancer Center (2014-0435)
    • 16 Apr 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top